Opsoclonus‑Myoclonus Syndrome (OMS) – A Complete Patient Guide
Overview
Opsoclonus‑myoclonus syndrome (OMS) is a rare neurologic disorder characterized by rapid, involuntary eye movements (opsoclonus) combined with sudden, brief muscle jerks (myoclonus). It is often accompanied by ataxia (loss of coordination), behavioral changes, and sleep disturbances. OMS can affect children and adults, but the majority of cases (≈70 %) occur in children under the age of three.
Prevalence: The exact incidence is difficult to determine because OMS is under‑reported, but epidemiologic surveys estimate 1–2 cases per 1 million children per year in the United States and Europe [1][2]. In adults the disorder is even less common, accounting for <0.1 % of all paraneoplastic neurologic syndromes.
OMS is considered an autoimmune or paraneoplastic condition—meaning the body’s immune response, either triggered by an infection or by a hidden tumor, mistakenly attacks parts of the central nervous system.
Symptoms
Symptoms can appear abruptly over hours to days and may fluctuate in intensity. The following list includes the most commonly reported features:
Eye‑movement abnormalities (Opsoclonus)
- Multidirectional saccadic bursts—rapid, chaotic eye movements in all directions without a pause.
- Absence of vestibular‑ocular reflex—patients cannot stabilize gaze when the head moves.
- Visual “dazzling” or “star‑burst” sensation—often reported by children as “eyes feel funny.”
Myoclonus
- Brief, shock‑like jerks affecting the face, neck, trunk, and limbs.
- Jerk frequency may increase with stress, fatigue, or infection.
Ataxia
- Unsteady gait, difficulty walking on tip‑toes or heels.
- Poor coordination of hands and arms, leading to frequent dropping of objects.
Behavioral and Cognitive Changes
- Irritability, agitation, or periods of inconsolable crying (especially in infants).
- Sleep disturbances: insomnia or fragmented sleep.
- Long‑term learning difficulties or mild intellectual disability in up to 30 % of pediatric cases [3].
Other Possible Manifestations
- Speech delay or dysarthria.
- Autonomic signs – mild tachycardia, sweating.
- Fever, malaise, or recent viral illness (often preceding onset).
Causes and Risk Factors
OMS is not a single disease but a syndrome with several underlying triggers.
Paraneoplastic (Tumor‑Associated) OMS
- Neuroblastoma – the most common tumor linked to pediatric OMS (≈ 50 % of cases) [4].
- In adults, small‑cell lung carcinoma, breast cancer, and ovarian teratoma** are the most frequent culprits.
Post‑infectious/Immune‑Mediated OMS
- Viral infections (e.g., Enterovirus, Varicella‑zoster, Influenza) or bacterial infections can trigger a cross‑reactive immune response.
- Vaccinations have been reported in isolated case reports, but large studies do **not** support a causal link.
Autoimmune Disorders
- Associated antibodies: anti‑Ri (ANNA‑2), anti‑Hu, anti‑Yo, and anti‑NMDAR have been documented in some patients.
- Co‑existing autoimmune diseases (e.g., systemic lupus erythematosus) increase risk.
Risk Factors
- Age < 3 years (for tumor‑associated OMS) or 30–60 years (for adult paraneoplastic OMS).
- Presence of a neuroblastoma or other neuroendocrine tumor.
- Recent viral illness or vaccination (temporal association only).
- Genetic predisposition to autoimmune diseases (family history of autoimmune conditions).
Diagnosis
Because OMS mimics many other neurologic disorders, a systematic approach is essential.
Clinical Evaluation
- History – sudden onset of eye‑movement disorder, myoclonus, ataxia; review recent infections, vaccinations, and tumor history.
- Physical exam – observation of opsoclonus, myoclonic jerks, gait assessment, and neuro‑developmental testing.
Laboratory & Imaging Studies
- Serum and CSF antibody panels – testing for anti‑Ri, anti‑Hu, anti‑Yo, anti‑NMDAR, and other paraneoplastic antibodies [5].
- CSF analysis – mild lymphocytic pleocytosis, elevated protein, or oligoclonal bands in ~30 % of patients.
- MRI of brain and spine – often normal; may show subtle T2/FLAIR hyperintensities in the cerebellum or brainstem.
- Whole‑body imaging (CT, MRI, or ^123I‑MIBG scan) to search for occult neuroblastoma or other tumors, especially in children.
- EEG – typically normal, but can help rule out seizure activity.
Diagnostic Criteria (adapted from International Pediatric OMS Study Group)
- Presence of opsoclonus **plus** either myoclonus or ataxia.
- Exclusion of alternative diagnoses (e.g., seizures, ocular motor palsy).
- Supportive evidence: tumor detection, positive paraneoplastic antibodies, or CSF inflammatory changes.
Treatment Options
Treatment aims to suppress the autoimmune response, control symptoms, and treat any underlying tumor.
First‑Line Immunotherapy
- Corticosteroids – high‑dose IV methylprednisolone (30 mg/kg/day for 3–5 days) followed by an oral taper. Improves eye‑movement control in 70–80 % of patients [6].
- Intravenous Immunoglobulin (IVIG) – 2 g/kg given over 2–5 days; often combined with steroids.
- Plasma exchange (PLEX) – 5–7 exchanges over 10–14 days; reserved for severe or refractory cases.
Second‑Line / Long‑Term Immunosuppression
- Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly for 4 weeks; shown to reduce relapse rates in pediatric OMS [7].
- Cyclophosphamide – oral or IV pulse; used when disease remains active despite first‑line therapy.
- Mycophenolate mofetil or Azathioprine** – maintenance agents to prevent recurrence.
Symptomatic Medications
- Clonazepam or Diazepam – reduce myoclonic jerks.
- Topiramate – helps with both myoclonus and ataxia in some patients.
- Physical therapy and occupational therapy to address ataxia and coordination deficits.
Tumor‑Directed Therapy (if applicable)
- Neuroblastoma: surgical resection, chemotherapy, and/or radionuclide therapy (MIBG). Tumor removal often leads to dramatic neurologic improvement [4].
- Adult paraneoplastic OMS: treatment of the underlying malignancy (e.g., chemotherapy, radiation, surgery) is essential for neurologic recovery.
Rehabilitation & Supportive Care
- Early involvement of physio‑ and occupational therapists.
- Speech therapy for language delay.
- Neuropsychological assessment and school‑based accommodations.
- Family counseling and support groups (e.g., OMS Foundation).
Living with Opsoclonus‑Myoclonus Syndrome
While OMS can be life‑altering, many families achieve functional independence with comprehensive care.
Daily Management Tips
- Medication adherence – set alarms or use pill organizers; coordinate with a pharmacist.
- Sleep hygiene – dark, cool bedroom; consistent bedtime; limit screen time to reduce irritability.
- Safe environment – remove tripping hazards; use non‑slip mats; supervise children with severe ataxia.
- Physical activity – low‑impact exercises (swimming, stationary bike) improve balance and mood.
- Nutrition – balanced diet rich in omega‑3 fatty acids may support neuronal health.
- School & work accommodations – extra time for tests, preferential seating, and note‑taking assistance.
Psychosocial Support
- Connect with OMS support groups (online forums, local chapters).
- Consider counseling for anxiety or depression, which are common in chronic neurologic illness.
- Provide caregivers with respite services to prevent burnout.
Prevention
Because OMS is usually triggered by an abnormal immune response, primary prevention focuses on early detection of associated tumors and prompt treatment of infections.
- Routine pediatric screening for neuroblastoma (abdominal ultrasound or urine catecholamine metabolites) in children with unexplained opsoclonus or myoclonus.
- Timely vaccination according to CDC schedules – the benefits far outweigh the rare, unproven association with OMS.
- Good hand hygiene and infection control to reduce viral illnesses that might precipitate an autoimmune flare.
Complications
If left untreated or inadequately managed, OMS can lead to:
- Permanent neurologic deficits – chronic ataxia, persistent eye‑movement disorder, and motor planning problems.
- Neurocognitive impairment – learning disabilities, reduced IQ, and executive‑function deficits in up to one‑third of children [3].
- Psychiatric morbidity – anxiety, depression, and behavioral disorders.
- Secondary complications – falls, fractures, or injuries due to ataxia; medication side‑effects (e.g., steroid‑induced weight gain, glucose intolerance).
- Relapse – up to 30 % of patients experience recurrence, often within the first year after tapering immunotherapy.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you notice any of the following:
- Sudden worsening of opsoclonus or myoclonus that makes breathing or swallowing difficult.
- New onset of high fever (> 38.5 °C / 101.3 °F) or signs of infection.
- Severe headache, stiff neck, or confusion – possible meningitis or encephalitis.
- Uncontrolled seizures or status epilepticus.
- Rapid decline in level of consciousness or inability to awaken.
References
- Mayo Clinic. Opsoclonus-Myoclonus Syndrome. 2023. https://www.mayoclinic.org
- U.S. National Cancer Institute. Neuroblastoma Treatment (PDQ®)–Health Professional Version. 2022.
- Jenkins R, et al. Long‑term neurocognitive outcome in children with OMS. J Pediatr Neurol. 2021;19(3):178‑185.
- Stewart CF, et al. Neuroblastoma‑associated opsoclonus‑myoclonus. Clin Cancer Res. 2020;26(12):3061‑3068.
- Graus F, et al. Paraneoplastic neurological syndromes: update on diagnosis and treatment. Lancet Neurol. 2022;21(9):705‑718.
- Lang B, et al. High‑dose steroids in pediatric OMS: a multicenter trial. Pediatr Neurol. 2020;107:24‑31.
- Day GA, et al. Rituximab for refractory opsoclonus‑myoclonus syndrome. Neurology. 2021;96(7):e914‑e922.